ATHEROLOAD® Test Services

Atherosclerotic plaque formation in the arteries is an early event in the pathological development of cardiovascular diseases. Early detection followed by proper medical intervention may help reverse this process and reduce the threat of developing life-threatening heart injury. Mounting evidence has shown that the number and size of low-density lipoprotein (LDL) and cholesterol particles are the most important risk factors in atherosclerosis. Plaxgen has developed a proprietary flow cytometry-based ATHEROLoad® assay for the non-invasive detection and measurement of LDL and high-density lipoprotein (HDL) particles for the diagnosis of atherosclerosis-related cardiovascular disease (Fig. 1). Using the ATHEROLoad® assay, serum samples were screened using fluorescence-labeled cholesterol and phospholipid-based aggregates to identify positive subjects. The resulting clinical data revealed that the serum samples from patients with atherosclerosis, but not age-matched controls, contain factors that contribute to the accelerated in vitro formation of plaque particles containing cholesterol and phospholipid.


StatRes® Test Services

Statins are a leading medicine prescribed to patients with cardiovascular disease to prevent both primary and secondary occurrences of a heart attack. There are currently 7 different statins on the market. Although the intensive use of statins leads to a reduction in LDL levels, there are variations among patients regarding the response to different statins. Doctors usually prescribe one type of statin to patients followed by a check-up 3-4 weeks later to determine the efficacy of the statin. If there is no efficacy, doctors will prescribe another type of statin. This can be a long process, and patients may become susceptible to drug toxicity. Our StatRes® test offers a personalized medical solution to patients on statins. Different types of statins can be tested in vitro on serum samples from patients. The statin that reduces the concentration of LDL particles and increases the concentration of HDL particles will become the doctor’s first choice to prescribe to the patient.

The Benefits of StatRes® Test

  • Patients receive at the start the statin that is most effective for them. No waiting period is necessary.
  • Drug toxicity due to the use of multiple statins can be significantly lowered.
  • Medical costs due to multiple statin trials can also be reduced.

AMYLOAD® Test Services

The progressive accumulation of amyloid plaques in the brain is the leading cause of Alzheimer’s disease (AD) and related dementia in patients. The early identification of AD in individuals remains a challenge for physicians, and the development of a biomarker-based, non-invasive assay will thus contribute significantly to the diagnosis of AD. Plaxgen’s patented AMYLoad® assay was developed for the non-invasive diagnosis of AD using serum samples. The assay method is based on the well-established scientific observations that the amyloid beta (abeta) and tau peptides play key roles in the pathogenesis of AD and that affected patients exhibit an abnormal clearance of these peptides in the blood and brain. The AMYLoad® assay is capable of detecting responses against Abeta and Tau peptides in the serum samples, that are related to the pathway of plaque formation. In the assay, serum-induced abeta and tau particles are detected, and their concentration is measured to identify and stratify AD patients (Fig. 1). Our initial results provide sufficient early clinical validation of the AMYLoad® assays for the diagnosis of AD using biomarkers in serum. The flow cytometry-based AMYLoad® assay provides a non-invasive and low-cost assay for the early diagnosis of AD.


ATHEROLOAD®, StatRes® and AMYLOAD® tests are developed by Plaxgen Inc and not approved by FDA. The results generated from these tests provide valuable information to Physicians for taking diagnostic decisions in conjunction with other diagnostic tests.